

DEC. 7. 2005 12:57PM

GLAXO WELLCOME

NO. 8677 P. 1

**RECEIVED
CENTRAL FAX CENTER**

DEC 07 2005



GlaxoSmithKline

FAX

To 1625

Company USPTO

Fax 571-273-8300

From Allyson K. Jacobs

Tel 919-483-9105 **Fax** 919-483-7988

E-mail aki27836@gsk.com

Date 12/7/05 **Pages including cover** 20

Subject Serial No.: 10/507,006;

Filing Date: 9/7/04

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Amendment Transmittal
Response to Restriction Requirement
Certificate of Transmission


The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

DEC. 7. 2005 12:57PM

GLAXO WELLCOME

NO. 8677

RECEIVED
CENTRAL FAX CENTER
P. 2
DEC 07 2005

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PK4654USW	
Applicant(s): Bhandari et al.					
Application No. 10/507,006	Filing Date 9/7/04	Examiner Niloofar Rahmani	Customer No. 23347	Group Art Unit 1625	Confirmation No. 8775
Invention: CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS					
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	51	54	0	x \$50.00	\$0.00
INDEP. CLAIMS	4	4	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____					
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392					
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.					
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
 Signature					
<div style="display: flex; justify-content: space-between;"><div>Amy H. Fix, Reg. No. 42,616 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8911 Facsimile: (919) 483-7988</div><div>Dated: 7 Dec 2005</div></div>					
<div style="display: flex; justify-content: space-between;"><div>cc:</div><div style="border: 1px solid black; padding: 5px; width: 45%;"><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____</p><p style="text-align: center;">(Date)</p><p style="text-align: center;">_____ Signature of Person Mailing Correspondence</p><p style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</p></div></div>					

P11LARGE/REV09

PK4654USW

**RECEIVED
CENTRAL FAX CENTER****DEC 07 2005****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Ashok BHANDARI et al.
Serial No.: 10/507,606
Filing Date: September 7, 2004
Title: CONDENSED HETEROCYCLIC COMPOUNDS AS
CALCITONIN AGONISTS

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION

Sir:

This paper is submitted in response to the Office Action mailed November 7, 2005, for which a 1-month shortened statutory period to respond was set. Accordingly, this paper is due to be filed on or before **December 7, 2005**. Early examination of the application on the merits is earnestly solicited.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. Should any other fees be deemed necessary for the timely filing of this paper, however, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 16 of this paper.